Guidant Shines Light on Vulnerable Plaque with Miravant Deal
Guidant appears to be the leader among the large cardiovascular device companies in pursuing device-based therapies for vulnerable plaque. The company's latest move in this space is a collaboration with Miravant Medical Technologies regarding using photodynamic therapy as a possible treatment for vulnerable plaque lesions.
You may also be interested in...
Boston Scientific CEO Jim Tobin, in a series of addresses, defends his company's decision to spend $27.3 billion on Guidant Inc., warts and all. Defying criticism of the deal, Tobin lays out how Boston Scientific management corrected Guidant's problems--and why the new company will thrive.
Biosensors International has not only developed a new stent, coating, and delivery technology in-house, but has also come up with its own drug, a rarity among small stent companies. Biosensors has adopted an aggressive dealmaking strategy much more akin to a large device or drug company, than a small firm. The result is that Biosensors has entered into alliances with big companies, including Guidant, and start-ups that have turned what until recently was a small interventional cardiology OEM company into one of the most innovative players in the drug-eluting stent market.
Several start-up companies are investigating a variety of new technologies to identify vulnerable plaque using, for example thermography, infrared, and optical coherence tomography. But the founder of TopSpin Medical believed that a technology already existed with the capability of differentiating lipid-rich from fibrotic tissue: magnetic resonance imaging. TopSpin has developed a system that creates a local magnetic field-inside a patient with a catheter-and creates an MR image. What's more, having the catheter close to the target tissue eliminates the motion artifacts that conventional external MRI systems experience when imaging pulsating coronary arteries.